Iron therapy transformed
Prescription iron therapies are not interchangeable! Ferralet 90 contains carbonyl iron and a unique, gentle formulation that transforms a patient's experience on iron therapy.
Individualized rate of absorption
The key to the safety and tolerability of Ferralet 90 is the biocomplementary manner in which it is solubilized and absorbed.* As gastric acid interacts with the carbonyl iron, it is solubilized for absorption.1 Balance is maintained between the production of soluble iron and its uptake by the intestines. Despite this more gradual absorption, however, the increases in mucosal ferritin, total absorption, and internal distribution are equivalent between carbonyl iron and ferrous sulfate.
Excellent tolerability and safety
This remarkable iron results in no significant difference in gastrointestinal side effects, even when dosed at 10 times the standard dose of ferrous sulfate.2 And it's far less toxic when ingested by children. In Conn's Current Therapy 2008, carbonyl iron is cited as "the oral therapy of choice for most persons, because it causes less gastrointestinal toxicity than iron salts and is equally effective in correcting iron deficiency."3
Designed to make iron therapy more pleasant for patients
Ferralet 90 addresses traditional drawbacks of iron therapy. The gentle stool softener docusate sodium eases constipation in iron-sensitive women. The vanilla scent improves the taste and smell normally associated with iron therapy. And, with a formulation free of lactose and gluten, many dietary concerns are met.
- Related Information
- Package Insert»
- Ferralet Website»
Important Safety Information
WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.
Warning
Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient.
Precautions
Administration of Drug- General: Take 2 hours after meals. Do not exceed recommended dose. Discontinue use if symptoms of intolerance appear. The type of anemia and underlying cause or causes should be determined before starting therapy with Ferralet® 90 tablets. Ensure Hgb, Hct, reticulocyte count are determined before starting therapy and periodically thereafter during prolonged treatment. Periodically review therapy to determine if it needs to be continued without change or if a dose change is indicated. This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.
- Folic Acid: Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive. Pernicious anemia should be excluded before using these products since folic acid may mask the symptoms of pernicious anemia.
- Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
- Geriatric Use: Dosing for elderly patients should be cautious. Due to the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy, dosing should start at the lower end of the dosing range.
This material is intended to provide basic information. Patients should discuss all medical advice, diagnosis, and treatment with their healthcare provider.
Please see full Prescribing Information
Ferralet 90 is available by prescription only. Please see the full Prescribing Information.
* Data based on animal studies.
- Huebers HA, Brittenham GM, Csiba E, Finch CA. Absorption of carbonyl iron. J Lab Clin Med. 1986 Nov;108(5):473-8.
- Gordeuk VR, Brittenham GM, McLaren CE, Hughes MA, Keating LJ. Carbonyl iron therapy for iron deficiency anemia. Blood 1986 Mar;67(3):745-752.
- Barton JC. Iron deficiency. In Rakel RE, Bope ET. Conn's Current Therapy, 2008. Amsterdam, The Netherlands: Saunders/Elsevier, 385-389.
More than 500,000 babies are born too soon each year. Some are so small they struggle to survive. This year, Mission Pharmacal is joining forces with the March of Dimes* as a National Corporate Sponsor to help raise awareness about the growing crisis of premature birth. To learn more and help us fight prematurity, click on the links below. For more than 60 years, Mission Pharmacal has been committed to providing products for healthy women and healthy babies.
Think twice about your choices for treating bacterial vaginosis.
Prescription iron therapies are not interchangeable! Ferralet 90 contains carbonyl iron and a unique, gentle formulation that transforms a patient's experience on iron therapy.
